Online inquiry

IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12502MR)

This product GTTS-WQ12502MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets MUC5AC gene. The antibody can be applied in Colorectal Cancer (CRC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001304359.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4586
UniProt ID P98088
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ12502MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6254MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CR-6261
GTTS-WQ7002MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA F-627
GTTS-WQ11119MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MDX-060
GTTS-WQ6298MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CS-1001
GTTS-WQ7091MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FE 999301
GTTS-WQ8748MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IBI-101
GTTS-WQ2535MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 477
GTTS-WQ12537MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA NPVPDR001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW